Daunorubicin\/cytarabine liposome is approved in several countries worldwide for the treatment of adults with therapy-related acute myeloid leukaemia (tAML) and AML with myelodysplasia-related changes (MRC). Approval was based on its clinical benefit in older patients with newly diagnosed high-risk\/secondary AML in a pivotal phase III trial. In this study, daunorubicin\/cytarabine liposome significantly prolonged overall survival (OS) and event-free survival (EFS) relative to conventional chemotherapy with cytarabine plus daunorubicin (hereafter referred to as 7 + 3).<\/p>\n
If VYXEOS (daunorubicin and cytarabine) liposome<\/strong>\u00a0are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n Note:<\/strong> News \/ Updates<\/p>\n VYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor,\u00a0<\/strong>that is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import VYXEOS (daunorubicin and cytarabine) liposome\u201d ba<\/strong>sed on the information you provide.<\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/p>\n\n
VYXEOS (daunorubicin and cytarabine) liposome for injection, for intravenous use Initial U.S. Approval: 2017<\/h2>\n
\nManufacturer: Jazz Pharmaceuticals, Inc.
\nDosage, Form & Strength: VYXEOS is a sterile, preservative-free, purple, lyophilized cake for reconstitution supplied in a single-dose clear glass vial as follows: \u2022 For injection: 44 mg daunorubicin and100 mg cytarabine encapsulated in liposomes. If you have any questions about your illness, talk to your doctor
\nSource Details:\u00a0Patient Information<\/a><\/p>\nAccess Patient Name Basis Treatment<\/h4>\n